Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Morbize Julieron is active.

Publication


Featured researches published by Morbize Julieron.


Journal of Clinical Oncology | 2006

Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial.

Jean Bourhis; M. Lapeyre; Jacques Tortochaux; Michel Rives; Mehdi Aghili; S. Bourdin; F. Lesaunier; Toufik Benassi; Claire Lemanski; Lionel Geoffrois; Antoine Lusinchi; Pierre Verrelle; E. Bardet; Morbize Julieron; P. Wibault; Monique Luboinski; Ellen Benhamou

PURPOSE With the aim to increase the dose intensity of radiation therapy (RT), and subsequently the locoregional control rate, a very accelerated RT regimen was compared with conventional RT in a series of patients with head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS Between 1994 and 1998, 268 patients with T3 or T4, N0 to N3 HNSCC (staged by 1997 International Union Against Cancer criteria) that was not eligible for surgery were randomly assigned to receive either conventional RT, delivering 70 Gy in 7 weeks to the primary tumor and 35 fractions of 2 Gy over 49 days, or to receive very accelerated RT, delivering 62 to 64 Gy in 31 to 32 fractions of 2 Gy over 22 to 23 days (2 Gy/fraction bid). RESULTS The most common tumor site was the oropharynx and most of the patients (70%) had T4 and N1 to N3 tumors in 72% of patients. The main patient and tumor characteristics were well-balanced between the two arms. The median total doses were 63 Gy (accelerated) and 70 Gy (conventional), with a median overall time of 22 days and 48 days, respectively. Acute mucositis was markedly increased in the accelerated-RT arm (P < .001). The locoregional control rate was improved by 24% at 6 years with accelerated RT. In contrast, disease-free survival and overall survival were not significantly different between the two arms. There was no difference in late effects between the two arms. CONCLUSION The very accelerated RT regimen was feasible and provided a major benefit in locoregional control but had a modest effect on survival.


Annals of Otology, Rhinology, and Laryngology | 1998

Reconstruction with Free Jejunal Autograft after Circumferential Pharyngolaryngectomy: Eighty-Three Cases

Germain Ma; Jean-Louis Bourgain; Morbize Julieron; G. Schwaab; P. Wibault; P. Marandas; B. Luboinski

The free jejunal autograft (FJA) has become a common procedure for pharyngeal reconstruction after circumferential pharyngolaryngectomy. In order to evaluate the postoperative outcome and the functional and carcinologic results, we retrospectively reviewed 83 cases of reconstruction with FJA. Fifty-one patients had received no prior radiotherapy, and 25 had received prior radiotherapy for their hypopharyngeal tumor or for another previous primary. Seven patients underwent a secondary reconstruction. In the postoperative course, there were 2 postoperative deaths, 4 graft failures (5%), and 11 salivary fistulas. The median time to removal of the nasogastric tube was 16 days, and to discharge, 23 days. Forty-eight patients received postoperative radiotherapy, with good tolerance. At 1 year postoperatively, 98% of the patients were able to eat a solid or soft diet. The postoperative radiotherapy did not impair the quality of the functional results in a long-term assessment. The vocal results were disappointing. The 3-year survival rate was 40%. The main carcinologic failures (45 patients) were locoregional recurrences (20 patients) and metastasis, which was the cause of death in 34% of the cases. It seems clear that FJA allows one-stage reconstruction and good swallowing rehabilitation, tolerates postoperative radiotherapy, and increases the quality of life in these patients with a poor prognosis.


Otolaryngology-Head and Neck Surgery | 2008

Botulinum toxin for radiation-induced facial pain and trismus

Dana M. Hartl; Myriam Cohen; Morbize Julieron; P. Marandas; Franéois Janot; Jean Bourhis

Objective To report the efficacy of botulinum toxin A for radiation-induced pain, trismus, and masticator spasm in head and neck cancer. Patients and Methods This prospective nonrandomized study included patients in complete remission with radiation-induced pain and trismus with or without masticator spasms. Fifty units of Botox (Allergan) or 250 units of Dysport (Ipsen) were injected transcutaneously into the masseter muscles. Jaw opening was measured and patients answered 20 questions about jaw opening, pain, and cramps, before injection at 1 month. Results Nineteen patients (7 women, 12 men) were included. Median time after radiation therapy was 5 years (range, 11 months to 22 years). At 1 month, no significant increase in jaw opening was recorded. Improvement was noted in the functional domain (P = 0.004), for pain (P = 0.002) and cramps (P = 0.004), but not in the social (P = 0.83) or emotional (P = 0.43) domains. No side effects occurred. Conclusions Botulinum toxin did not improve trismus but significantly improved pain scores and masticator spasms (oromandibular dystonia).


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2005

Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma.

S. Temam; Venkata N. Koka; G. Mamelle; Morbize Julieron; Romain Carmantrant; P. Marandas; F. Janot; Jean Bourhis; B. Luboinski

The morbidity and mortality rates of salvage surgery in patients with local recurrence of head and neck squamous cell carcinoma (HNSCC) after radiotherapy are high. The aim of this study was to determine the rate of occult neck node metastasis and the surgical morbidity of patients after salvage surgery for local relapse after definitive radiotherapy.


European Archives of Oto-rhino-laryngology | 2001

Subtotal laryngectomy with cricohyoidopexy as first treatment procedure for supraglottic carcinoma: Institut Gustave-Roussy experience (146 cases, 1974-1997).

G. Schwaab; Frédéric Kolb; Morbize Julieron; F. Janot; Anne Marie Le Ridant; G. Mamelle; P. Marandas; Venkata N. Koka; B. Luboinski

Patients and methods: Between 1974 and 1997, 297 patients underwent a subtotal laryngectomy at the Institut Gustave-Roussy; 146 of these patients underwent cricohyoidopexy (CHP) for a supraglottic primary as their first treatment. The majority of patients were men (137) aged from 33 to 78 years (median 54 years). The tumour stage at presentation was T1 in 2, T2 in 87, T3 in 53 (pre-epiglottic space involvement), and T4 (minimal thyroid cartilage invasion) in 4 patients. One hundred and twenty-five patients were N0 (86%) and 21 patients were Np (palpable); 98% had homolateral and 55% had bilateral neck dissections. Results: One patient died postoperatively of a myocardial infarction and 68% patients had an uneventful course. Aspiration was the commonest complication (23 patients, 19%). The median time to removal of the tracheotomy cannula was 10 days and for the nasogastric tube 21 days during the past 10 years. Completion of subtotal laryngectomy into total laryngectomy was done in 21 cases (15%): eight times because of oncological events [five local failures, two second primary (hypopharynx), one positive margin] and 13 times because of aspiration (9%). There were six local failures (4%) and eight nodal failures (5%). The rates of distant metastases and second primaries were 6% and 16% respectively. Half of the local and nodal failures were subsequently sterilized. Findings at death were two local recurrences, four nodal recurrences, eight distant metastases, and 11 second primaries. The 3- and 5-year overall survival rates were 92% and 88% respectively, with an overall laryngeal preservation rate of 86%. Conclusion: When supraglottic laryngectomy is not feasible for supraglottic cancer, subtotal laryngectomy with CHP is a safe and effective oncological procedure, with preservation of satisfactory laryngeal function.


Journal of Laryngology and Otology | 1998

Combined transfacial and neurosurgical approach to malignant tumours of the ethmoid sinus

D. Salvan; Morbize Julieron; P. Marandas; F. Janot; A. M. Leridant; C. Domenge; G. Mamelle; G. Schwaab; B. Luboinski

In order to understand the risks and benefits of a combined transfacial and neurosurgical procedure for neoplasms of the ethmoid sinus, we reviewed all patients who underwent this surgical approach in our department between 1986 and 1994. The study included 41 patients. Pathological diagnoses included adenocarcinoma (31 patients), squamous cell carcinoma (three patients), aesthesioneuroblastoma (three patients), other (four patients). The overall morbidity rate was 39 per cent, and the post-operative mortality rate was 2.5 per cent. Complications were statistically more likely in patients with bone skull base reconstruction. The main carcinologic failures were local recurrences (24 per cent) and metastases (22 per cent). The one-year, three-year and five-year Kaplan Meir survival rates were respectively 84 per cent, 53 per cent and 36 per cent. In conclusion, the mortality and morbidity were acceptable, especially when no bone skull base reconstruction was performed. Better local control justifies a combined procedure with post-operative radiotherapy when tumours involve or reach the skull base.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2001

Surgical management of posterior pharyngeal wall carcinomas: Functional and oncologic results

Morbize Julieron; Frédéric Kolb; G. Schwaab; P. Marandas; Valérie Billard; Antoine Lusinchi; Anne-Marie Le Ridant; B. Luboinski

The optimal primary treatment for posterior pharyngeal wall tumors remains controversial.


Clinical Cancer Research | 2004

Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma

Stéphane Temam; Odile Casiraghi; Jean Baptiste Lahaye; Jacques Bosq; Xian Zhou; Morbize Julieron; G. Mamelle; J. Jack Lee; Li Mao; B. Luboinski; Jean Bénard; F. Janot

Purpose: Postoperative radiotherapy is used to prevent local recurrence of head and neck squamous cell carcinoma in patients with positive surgical margins. We sought to determine whether tetranucleotide microsatellite instability could be detected in surgical margins and used to predict local recurrence. Experimental Design: We prospectively collected tumor and surgical margin specimens from patients with head and neck squamous cell carcinoma who had undergone surgical resection at Institut Gustave-Roussy during a 1-year period. Margins were considered positive if extensive pathological examination revealed either carcinoma within 5 mm or dysplasia. We tested five tetranucleotide microsatellite markers (UT5085, L17686, D9S753, ACTBP2, and CSF1R) in the tumor specimens and paired surgical margins of the patients whose margins were negative on pathological examination. Results: Pathological examination revealed that among the 76 patients, 22 had positive margins; therefore, these patients were excluded. Of the 54 remaining patients, 26 (48%) had tumors informative for markers UT5085, L17686, or both; the other 3 markers were not informative. Seven (27%) of the 26 informative tumors had the same instability pattern in the surgical margins. At a median follow-up of 26 months, 5 of the 7 local recurrences occurred in patients with molecularly positive surgical margins. A strong, independent association was found between positive surgical margins and local recurrence (P = 0.01; hazard ratio, 6.49). Conclusions: Tetranucleotide microsatellite instability in surgical margins may be a useful biomarker to predict local recurrence of head and neck squamous cell carcinoma in patients with apparently disease-free margins.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2006

FUNCTIONAL RESULTS WITH ADVANCED HYPOPHARYNGEAL CARCINOMA TREATED WITH CIRCULAR NEAR-TOTAL PHARYNGOLARYNGECTOMY AND JEJUNAL FREE-FLAP REPAIR

S. Temam; F. Janot; Germain Ma; Morbize Julieron; Evelyne Bretagne; Jeffrey N. Myers; P. Marandas; G. Mamelle; Anne Marie Leridant; Frédéric Kolb; B. Luboinski

Patients treated by a circular pharyngolaryngectomy for advanced hypopharyngeal carcinoma have a poor prognosis and disappointing speech restoration.


Investigational New Drugs | 1995

Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model.

Luis H. Ramirez; Morbize Julieron; Marc Bonnay; Serge Koscielny; Zhongxin Zhao; Alain Gouyette; Jean-Nicolas Munck

Suramin is an antitrypanosomal compound with confirmed efficacy against several human malignancies. It is generally assumed that its mechanism of action includes the interaction with different growth factors, unlike most of the anticancer drugs. Its anticancer activity has not been testedin vivo against squamous cell carcinoma. The purpose of this study was to assess the efficacy and toxicity of suraminin vivo andin vitro on the VX2 tumor model at therapeutic monitored plasma concentrations. We determined the pharmacokinetics of suramin in rabbits, and modelized its administration in order to obtain plasma concentrations between 150 and 300 μg/ml throughout the treatment course of 3 weeks. Under these conditions, antitumor effects of suramin were evaluatedin vivo by comparing liver tumor involvement in suramin-treated and control rabbits. Liver involvement was quantified by image analysis andin vitro effects were also determined at the same concentrations.In vivo, suramin promoted liver tumor growth significantly (p<0.05), compared to untreated controls.In vitro, suramin significantly stimulated tumor cell growth at concentrations above 200 μg/ml (p<0.01). Suramin may have stimulatory effects on tumor growth in squamous cell carcinoma at relevant plasma drug concentrations. Caution should be taken in further trials in patients with squamous cell carcinomas.

Collaboration


Dive into the Morbize Julieron's collaboration.

Top Co-Authors

Avatar

B. Luboinski

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

P. Marandas

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

F. Janot

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

G. Schwaab

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

G. Mamelle

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

Germain Ma

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stéphane Temam

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge